IL172735A0 - Dispersible formulation of an anti-inflammatory agent - Google Patents

Dispersible formulation of an anti-inflammatory agent

Info

Publication number
IL172735A0
IL172735A0 IL172735A IL17273505A IL172735A0 IL 172735 A0 IL172735 A0 IL 172735A0 IL 172735 A IL172735 A IL 172735A IL 17273505 A IL17273505 A IL 17273505A IL 172735 A0 IL172735 A0 IL 172735A0
Authority
IL
Israel
Prior art keywords
inflammatory agent
dispersible formulation
dispersible
formulation
inflammatory
Prior art date
Application number
IL172735A
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of IL172735A0 publication Critical patent/IL172735A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL172735A 2003-07-31 2005-12-21 Dispersible formulation of an anti-inflammatory agent IL172735A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31
PCT/IB2004/002461 WO2005009436A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
IL172735A0 true IL172735A0 (en) 2006-04-10

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172735A IL172735A0 (en) 2003-07-31 2005-12-21 Dispersible formulation of an anti-inflammatory agent

Country Status (14)

Country Link
EP (1) EP1651210A1 (en)
JP (1) JP2007500691A (en)
KR (1) KR100780983B1 (en)
CN (1) CN1829510A (en)
AU (1) AU2004258745A1 (en)
BR (1) BRPI0412581A (en)
CA (1) CA2533101A1 (en)
CO (1) CO5650245A2 (en)
IL (1) IL172735A0 (en)
MX (1) MXPA06001288A (en)
NO (1) NO20060982L (en)
RU (1) RU2319508C2 (en)
WO (1) WO2005009436A1 (en)
ZA (1) ZA200600096B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (en) 2006-12-20 2008-10-17 Schering Plough Ltd PHARMACEUTICAL COMPOSITIONS OF FLUNIXIN
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
UA111147C2 (en) * 2009-11-11 2016-04-11 Байєр Б.В. METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF EXTERNAL OTITIS
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
ES2391721T3 (en) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Transparent aqueous solutions of fluocinolone acetonide for the treatment of ear swelling
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
RU2486905C1 (en) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Method of treating mastitis in animals
CN102784161A (en) * 2012-08-01 2012-11-21 张吉川 Specific ear drops for treating acute/chronic tympanitis
EP2925367B1 (en) * 2013-01-14 2019-08-14 InFirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
LV15071B (en) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Composition for treatment of subclinical mastitis in cows
PE20181153A1 (en) 2015-08-05 2018-07-17 Childrens Medical Center COMPOSITIONS WITH PRIZE POTENTIALS FOR THE SUPPLY OF DRUGS
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
KR101738815B1 (en) * 2015-08-27 2017-05-23 심민보 Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus comprising platelet-rich plasma and method using the same
WO2019191547A1 (en) * 2018-03-29 2019-10-03 Yale University Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation
RU2749857C1 (en) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Method for combatting otitis media and otitis externa
RU2751697C1 (en) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Remedy for treatment of otitis of external auditory canal in dogs
KR102461699B1 (en) * 2021-05-21 2022-11-03 현대약품 주식회사 Gargle solution with improved stability comprising benzidamine hydrochloride
WO2023101421A1 (en) * 2021-12-03 2023-06-08 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus
KR20230084419A (en) * 2021-12-03 2023-06-13 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
MX9702699A (en) * 1994-10-26 1997-06-28 Novartis Ag Pharmaceutical compositions.
DE69620136T2 (en) * 1995-06-06 2002-08-01 Bayer Ag ANTIBACTERIAL PREPARATIONS FOR THE EARS WITHOUT IRRITATING, SENSITIZING AND OTOTOXIC EFFECTS
DZ2479A1 (en) * 1997-05-05 2003-02-01 Pfizer Anti-inflammatory selective co-2 inhibitor compounds and pharmaceutical compositions containing them.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
AU2001268512A1 (en) * 2000-06-16 2002-01-02 Hercules Incorporated Chemically-modified peptides, compositions, and methods of production and use
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20020068065A1 (en) * 2000-09-12 2002-06-06 Ondrej Hendl Pharmaceutical composition having specific water activity
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
WO2005009436A1 (en) 2005-02-03
CA2533101A1 (en) 2005-02-03
EP1651210A1 (en) 2006-05-03
CO5650245A2 (en) 2006-06-30
BRPI0412581A (en) 2006-09-19
MXPA06001288A (en) 2006-04-11
WO2005009436A8 (en) 2005-05-06
RU2319508C2 (en) 2008-03-20
AU2004258745A1 (en) 2005-02-03
KR100780983B1 (en) 2007-11-30
KR20060031873A (en) 2006-04-13
NO20060982L (en) 2006-05-02
CN1829510A (en) 2006-09-06
ZA200600096B (en) 2007-02-28
RU2006101628A (en) 2006-08-27
JP2007500691A (en) 2007-01-18

Similar Documents

Publication Publication Date Title
PL1608407T3 (en) Dispersible formulation of an anti-inflammatory agent
IL172735A0 (en) Dispersible formulation of an anti-inflammatory agent
HK1081457A1 (en) Dispersible pharmaceutical compositions
EP1576150A3 (en) Methods and compositions for increasing the efficacy of biologically-active ingredients
IS7037A (en) Use of HMG components as an anti-inflammatory agent
AU2731302A (en) Use of cci-779 as an antineoplastic agent
ZA200508997B (en) Preparation of an osteoinductive agent
EP1587482A4 (en) Anti-inflammatory compositions and uses thereof
AU2003304576A1 (en) Cis-hydrogenated fatty acid coating of medical devices
AU2003220968A1 (en) Anti-inflammatory agent
GB0207438D0 (en) Formulation
AU2003272719A1 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
GB0205504D0 (en) Formulation
AU2575201A (en) Use of hsp27 as an anti-inflammatory agent
HUP0302867A3 (en) Parasiticidal compositions and methods of their use
AU2003302372A1 (en) Formulations of finasteride
PL372655A1 (en) Compositions of pentafluoropropane
AU2003289207A1 (en) Anti-inflammatory agent
EP1534293A4 (en) Anti-inflammatory compositions and methods of use
PL371295A1 (en) Hfa-suspension formulation of an anhydrate
AU2003300543A1 (en) Slow release formulation of clarithromycin
GB0122731D0 (en) Anti-inflammatory agent
PT1576951E (en) Formulations for the rectal administration of thrombolytically-active agents
GB0116079D0 (en) Formulation of anti-inflammatory compositions
GB0318663D0 (en) Rolling formulation